Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

SOL-116 - BEYOND Bssl Targeting Therapy Towards Non-immunosuppressive Ra Treatment

Coordinator
Lipum AB, Sweden
Runs
1 July 2026 to 30 June 2029
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
4 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101287619

What the project is doing

In the project's own words, from its summary on CORDIS.

Rheumatoid arthritis (RA) remains a devastating autoimmune disease, affecting 5 million Europeans. Despite advances with biologics and JAK inhibitors, up to 40% of patients fail to respond or lose efficacy, while current treatments rely on broad immunosuppression, exposing patients to severe infections and long-term complications. There is an urgent unmet need for safer, more effective therapies. The SOL-116-BEYOND project directly addresses this gap by advancing SOL-116, a first-in-class humanized monoclonal antibody developed by Lipum, targeting bile salt-stimulated lipase (BSSL)—a previously overlooked driver of inflammation.

Unlike existing biologics, SOL-116 interrupts inflammation while sparing normal immune function. Building on strong preclinical data and Phase I results confirming safety, target engagement, and favorable pharmacokinetics, BEYOND will further develop SOL-116 through a phase 2 clinical trial, to demonstrate efficacy in the target population, enabling out licensing and further commercialisation. BEYOND is structured in three pillars: (1) a multicenter phase 2a clinical trial to establish efficacy and safety, (2) biomarker discovery and mechanistic insights to validate BSSL as a therapeutic target and enable patient stratification, and (3) health economics and patient-centered research to demonstrate societal and market value.

The lean, highly complementary consortium, comprising Lipum (developer of SOL-116), Age labs (Immunology/bioanalytics), Centre for Human Drug Research (clinical trials advisor) and MERAccess (health-economics), ensures scientific excellence, operational feasibility, and translational impact. BEYOND will pioneer safer, non-immunosuppressive RA treatment, strengthen Europe’s leadership in precision immunology, and position the consortium at the forefront of biotech innovation.

SOL-116 has the potential to reduce disability, improve quality of life, and achieve multi-billion-euro savings for European healthcare systems.

Topics

Who is involved

OrganisationCityCountryRole
Lipum ABUmeaSwedenCoordinator
Stichting Centre for Human Drug ResearchLeidenNetherlandsParticipant
Age Labs ASOsloNorwayParticipant
MERAccess ABTyresoSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI